Insulet Valuation
Is PODD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PODD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PODD * (MX$5519.04) is trading above our estimate of fair value (MX$3690.15)
Significantly Below Fair Value: PODD * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PODD *?
Key metric: As PODD * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PODD *'s PE Ratio? | |
|---|---|
| PE Ratio | 43.4x |
| Earnings | US$420.90m |
| Market Cap | US$18.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.5x |
| Enterprise Value/EBITDA | 45.7x |
| PEG Ratio | 23.9x |
Price to Earnings Ratio vs Peers
How does PODD *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.3x | ||
688271 Shanghai United Imaging Healthcare | 68.4x | 32.3% | CN¥108.2b |
STMN Straumann Holding | 61.3x | 20.9% | CHF 17.7b |
7733 Olympus | 32.2x | 14.4% | JP¥2.8t |
SOON Sonova Holding | 31.4x | 8.7% | CHF 18.8b |
PODD * Insulet | 43.4x | 1.8% | Mex$18.2b |
Price-To-Earnings vs Peers: PODD * is good value based on its Price-To-Earnings Ratio (43.4x) compared to the peer average (48.7x).
Price to Earnings Ratio vs Industry
How does PODD *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: PODD * is expensive based on its Price-To-Earnings Ratio (43.4x) compared to the Global Medical Equipment industry average (28.2x).
Price to Earnings Ratio vs Fair Ratio
What is PODD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 43.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PODD *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$5,519.04 | Mex$5,590.83 +1.3% | 7.9% | Mex$6,450.25 | Mex$4,761.39 | n/a | 22 |
| Nov ’25 | n/a | Mex$4,886.37 0% | 9.3% | Mex$5,615.61 | Mex$3,645.22 | n/a | 21 |
| Oct ’25 | n/a | Mex$4,750.87 0% | 9.2% | Mex$5,589.76 | Mex$3,628.44 | n/a | 21 |
| Sep ’25 | n/a | Mex$4,667.05 0% | 7.4% | Mex$5,202.09 | Mex$3,645.41 | n/a | 21 |
| Aug ’25 | n/a | Mex$3,970.91 0% | 9.0% | Mex$4,588.95 | Mex$3,144.28 | n/a | 21 |
| Jul ’25 | n/a | Mex$3,970.91 0% | 9.0% | Mex$4,588.95 | Mex$3,144.28 | n/a | 21 |
| Jun ’25 | n/a | Mex$3,970.91 0% | 9.0% | Mex$4,588.95 | Mex$3,144.28 | n/a | 21 |
| May ’25 | Mex$2,852.19 | Mex$3,859.97 +35.3% | 7.0% | Mex$4,411.10 | Mex$3,398.18 | n/a | 20 |
| Apr ’25 | n/a | Mex$3,925.49 0% | 7.0% | Mex$4,488.53 | Mex$3,457.83 | n/a | 20 |
| Mar ’25 | Mex$2,907.38 | Mex$4,047.30 +39.2% | 7.6% | Mex$4,615.41 | Mex$3,555.57 | n/a | 20 |
| Feb ’25 | n/a | Mex$3,989.56 0% | 11.5% | Mex$4,637.71 | Mex$2,799.80 | n/a | 20 |
| Jan ’25 | n/a | Mex$3,861.49 0% | 13.5% | Mex$4,598.72 | Mex$2,776.26 | n/a | 20 |
| Dec ’24 | Mex$3,243.00 | Mex$3,767.33 +16.2% | 16.1% | Mex$4,796.96 | Mex$2,792.52 | n/a | 20 |
| Nov ’24 | n/a | Mex$4,570.09 0% | 21.1% | Mex$6,448.26 | Mex$2,942.58 | n/a | 20 |
| Oct ’24 | n/a | Mex$4,794.52 0% | 17.5% | Mex$6,232.10 | Mex$3,247.71 | n/a | 18 |
| Sep ’24 | n/a | Mex$4,838.62 0% | 15.0% | Mex$5,970.04 | Mex$3,497.94 | n/a | 18 |
| Aug ’24 | n/a | Mex$5,891.39 0% | 8.7% | Mex$6,397.50 | Mex$3,992.04 | n/a | 18 |
| Jul ’24 | n/a | Mex$6,158.75 0% | 8.6% | Mex$6,676.01 | Mex$4,165.83 | n/a | 18 |
| Jun ’24 | Mex$4,808.00 | Mex$6,158.75 +28.1% | 8.6% | Mex$6,676.01 | Mex$4,165.83 | n/a | 18 |
| May ’24 | n/a | Mex$6,082.80 0% | 8.7% | Mex$6,765.15 | Mex$4,221.45 | Mex$2,852.19 | 17 |
| Apr ’24 | n/a | Mex$5,965.41 0% | 9.3% | Mex$6,758.40 | Mex$4,217.24 | n/a | 16 |
| Mar ’24 | n/a | Mex$5,951.33 0% | 9.8% | Mex$6,788.59 | Mex$4,236.08 | Mex$2,907.38 | 16 |
| Feb ’24 | Mex$5,363.75 | Mex$5,963.66 +11.2% | 11.7% | Mex$6,698.06 | Mex$4,133.66 | n/a | 16 |
| Jan ’24 | n/a | Mex$6,063.18 0% | 12.0% | Mex$6,846.91 | Mex$4,225.52 | n/a | 16 |
| Dec ’23 | n/a | Mex$5,847.51 0% | 12.0% | Mex$6,774.11 | Mex$4,180.59 | Mex$3,243.00 | 16 |
| Nov ’23 | n/a | Mex$5,476.18 0% | 12.5% | Mex$6,829.76 | Mex$3,761.32 | n/a | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
1.2%
1Y
-31.0%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a